Subscribe To
CNTX / Context Therapeutics ends 1Q with $45.7M as it gears up for 'pivotal' 2022
CNTX News
By Proactive Investors
October 31, 2023
Context Therapeutics reveals ‘encouraging' preclinical data for CTIM-76 tumor treatment
Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6 more_horizontal
By Proactive Investors
August 10, 2023
Context Therapeutic says it has enough cash to fund operation into late 2024
Context Therapeutics (NASDAQ:CNTX) Inc. has announced its financial results for the second quarter ended June 30, 2023, highlighting that it has suffi more_horizontal
By Proactive Investors
May 11, 2023
Context Therapeutics says focus on preclinical cancer therapeutic extends cash runway into late 2024
Context Therapeutics said its decision made during the first quarter to focus on developing its preclinical asset CTIM-76 has extended the company's c more_horizontal
By Proactive Investors
April 16, 2023
Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting, will host webinar
Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, more_horizontal
By Proactive Investors
March 23, 2023
Context Therapeutics announces pipeline update with FY 2022 financial results
Context Therapeutics (NASDAQ:CNTX) has announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway more_horizontal
By Proactive Investors
March 15, 2023
Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting
Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, more_horizontal
By Proactive Investors
February 6, 2023
Context Therapeutics highlights clinical responses from clinical trial evaluating ONA-XR to treat endometrial cancer
Context Therapeutics (NASDAQ:CNTX) Inc has highlighted encouraging clinical responses from its Phase 2 OATH clinical trial evaluating ONA-XR to treat more_horizontal
By Proactive Investors
January 9, 2023
Context Therapeutics announces manufacturing agreement with Lonza for bispecific antibody targeting Claudin 6 positive cancers
Context Therapeutics (NASDAQ:CNTX) Inc said it will be collaborating with Lonza, a global development and manufacturing partner to the pharma, biotech more_horizontal
